linolelaidic acid | 28290-78-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: linolelaidic acid
• 英文别名: (E,E)-6,9-octadecadienoic acid；Octadecadien-(6,9)-saeure-(1)；trans,trans-Octadeca-6,9-diensaeure；octadeca-6,9-dienoic acid；6,9-octadecadienoic acid；Octadeca-6,9-diensaeure；6E,9E-octadecadienoic acid；(6E,9E)-octadeca-6,9-dienoic acid
• CAS: 28290-78-0
• 化学式: C₁₈H₃₂O₂
• 分子量: 280.451
• InChiKey: ZMKDEQUXYDZSNN-OKLKQMLOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  20
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Bis-Platinum Complexes With Antitumor Activity
  申请人：Bernareggi Alberto

  公开号：US20100292322A1

  公开（公告）日：2010-11-18

  A compound of general formula (I): in which: R is selected from the group consisting of (C 1 -C 25 )alkyl, (C 2 -C 25 )alkenyl, aryl, (C 7 -C 10 )aralkyl; n and m are each independently an integer of two to eight; p is one or two; A is selected from the group consisting of —B—, —B—(CH 2 ) r —B—, —B—(CH 2 ) r —B—(CH 2 ) z —B—, wherein r and z are an integer from 2 to 8 , B is a —NR 1 — or —N(R 2 ) 2 + 1 /pQ −p group, in which R1 is selected from hydrogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )acyl, tert-butoxycarbonyl, and R 2 is selected from hydrogen and (C 1 -C 4 )alkyl; Q −p is an anion selected from chloride, bromide, iodide, nitrate, sulphate, hydrogen sulphate, perchlorate, R 3 COO − wherein R 3 has the same meanings as R, independently from one another and R 4 —O—SO 3 − wherein R 4 is (C 2 -C 14 )alkyl with the proviso that, when Q −p is selected from chloride, bromide, iodide, nitrate, sulphate, hydrogen sulphate, perchlorate, R is not (C 1 -C 4 )alkyl.

  一个通式（I）的化合物：其中：R选自（C1-C25）烷基，（C2-C25）烯烃，芳基，（C7-C10）芳基烷基的群组；n和m分别独立地为2到8的整数；p为1或2；A选自—B—，—B—（CH2）r—B—，—B—（CH2）r—B—（CH2）z—B—的群组，其中r和z为2到8的整数，B为—NR1—或—N(R2)2+1/pQ−p群，其中R1选自氢，（C1-C4）烷基，（C1-C4）酰基，叔丁氧羰基，R2选自氢和（C1-C4）烷基；Q−p选自氯化物，溴化物，碘化物，硝酸盐，硫酸盐，氢硫酸盐，高氯酸盐，R3COO−其中R3与R具有相同的含义，独立地为R4—O—SO3−其中R4为（C2-C14）烷基，但当Q−p选自氯化物，溴化物，碘化物，硝酸盐，硫酸盐，氢硫酸盐，高氯酸盐时，R不是（C1-C4）烷基。
• Compositions comprising reverse isomers of conjugated linoleic acid
  申请人：Saebo Asgeir

  公开号：US20050215641A1

  公开（公告）日：2005-09-29

  The present invention relates to the field of human and animal nutrition, and in particular to certain novel compositions of conjugated linoleic acids (CLA). In particular, the present invention relates to CLA compositions comprising the c10,t12, c10,c12, t9,c11 and c9,c11 isomers of conjugated linoleic acid.

  本发明涉及人类和动物营养领域，特别是某些新颖的共轭亚油酸（CLA）组合物。具体而言，本发明涉及包含共轭亚油酸的c10,t12、c10,c12、t9,c11和c9,c11异构体的CLA组合物。
• Functional acylglycerides
  申请人：Natural ASA

  公开号：US20030144353A1

  公开（公告）日：2003-07-31

  The present invention relates to the field of human and animal nutrition, and in particular to certain novel compositions of conjugated linoleic acids (CLA). In particular, the present invention relates certain isomers of conjugated linoleic acids at either the SN1 and SN3 or SN2 positions of the acylglyceride molecule and another fatty acyl residue at the other of the SN1 and SN3 or SN2 positions of the acylglyceride molecule. These novel acylglyceride compositions containing conjugated linoleic acyl residues, medium chain fatty acyl residues, long chain fatty acyl residues, and &ohgr;3, &ohgr;6, and &ohgr;9 fatty acyl residues are efficacious as pharmaceutical compositions, animal feed additives, and human dietary supplements.

  本发明涉及人类和动物营养领域，特别是某些共轭亚油酸（CLA）的新型组合物。具体而言，本发明涉及在酰基甘油分子的SN1和SN3或SN2位置上的某些共轭亚油酸异构体以及在酰基甘油分子的SN1和SN3或SN2位置上的另一种脂肪酰残基。这些新型酰基甘油组成物包含共轭亚油酸酰残基、中链脂肪酰残基、长链脂肪酰残基和&ohgr;3、&ohgr;6和&ohgr;9脂肪酰残基，可作为制药组合物、动物饲料添加剂和人类膳食补充剂。
• NANOPARTICLE DRUG DELIVERY SYSTEMS
  申请人：UNIVERSITY OF NOTRE DAME DU LAC

  公开号：US20160038607A1

  公开（公告）日：2016-02-11

  The invention provides pharmaceutical compositions and method of using the compositions, wherein the compositions comprise liposomes or micelles that contain one or more targeting peptides and/or anticancer drugs. In various embodiments, the components of the liposomes can include a) a phospholipid and optionally a lipid that is not a phospholipid; b) a pegylated lipid; c) a peptide-ethylene glycol (EG)-lipid conjugate wherein the peptide is a targeting ligand, and d) one or more drug-conjugated lipid, encapsulated drugs, or a combination thereof. The peptide-EG-lipid conjugate can be, for example, a compound of Formula (I) or Formula (II). The ethylene glycol (EG) segments of the peptide-EG-lipid conjugate can be, for example, EG6 to about EG36; and the EG segment can be conjugated to one or more lysine moieties.

  本发明提供了药物组合物及其使用方法，其中该组合物包含脂质体或胶束，其中包含一种或多种靶向肽和/或抗癌药物。在各种实施例中，脂质体的组分可以包括a）磷脂和可选的非磷脂类脂质；b）聚乙二醇化脂质；c）肽-乙二醇（EG）-脂质共轭物，其中肽是靶向配体，并且d）一种或多种药物共轭脂质，封装药物或其组合物。肽-EG-脂质共轭物可以是例如公式（I）或公式（II）的化合物。肽-EG-脂质共轭物的乙二醇（EG）片段可以是例如EG6到约EG36；并且EG片段可以与一个或多个赖氨酸基团结合。
• Process for production of omega 9 type polyunsaturated fatty acid
  申请人：SUNTORY LIMITED

  公开号：EP0535939A1

  公开（公告）日：1993-04-07

  A process for production of omega 9 type polyunsaturated fatty acid or a lipid containing said fatty acid, comprising the steps of culturing a microorganism having an ability to produce omega 9 type polyunsaturated fatty acid or a lipid containing said fatty said, and recovering the omega 9 type polyunsaturated fatty acid or the lipid containing said fatty acid.

  一种生产欧米伽 9 型多不饱和脂肪酸或含有所述脂肪酸的脂质的工艺，包括以下步骤：培养具有生产欧米伽 9 型多不饱和脂肪酸或含有所述脂肪酸的脂质的能力的微生物，以及回收欧米伽 9 型多不饱和脂肪酸或含有所述脂肪酸的脂质。